tiprankstipranks
Advertisement
Advertisement

GMAB Stock Latest News

Genmab Grants New Restricted Stock Units and Warrants to Employees
Company AnnouncementsGenmab Grants New Restricted Stock Units and Warrants to Employees
8h ago
6K
GMAB
Genmab Trial Setback: Terminated Melanoma Study Adds Uncertainty to GMAB’s Immuno-Oncology Outlook
PremiumCompany Announcements
Genmab Trial Setback: Terminated Melanoma Study Adds Uncertainty to GMAB’s Immuno-Oncology Outlook
10h ago
GMAB
Genmab presents EPCORE FL-1 subgroup data at EHA 2026 Congress
PremiumThe Fly
Genmab presents EPCORE FL-1 subgroup data at EHA 2026 Congress
11h ago
GMAB
Genmab Advances Rina-S Into Phase 3 Ovarian Cancer Trial, Setting Up a New Long-Term Catalyst
PremiumCompany Announcements
Genmab Advances Rina-S Into Phase 3 Ovarian Cancer Trial, Setting Up a New Long-Term Catalyst
8d ago
GMAB
Genmab Expands Rina-S Ovarian Cancer Program in China, Raising Long-Term Upside Potential
PremiumCompany Announcements
Genmab Expands Rina-S Ovarian Cancer Program in China, Raising Long-Term Upside Potential
9d ago
GMAB
Genmab Reports Board Member Share Sale Under EU Market Abuse Rules
PremiumCompany AnnouncementsGenmab Reports Board Member Share Sale Under EU Market Abuse Rules
13d ago
6K
GMAB
Genmab assumed with a Buy at Truist
Premium
The Fly
Genmab assumed with a Buy at Truist
15d ago
GMAB
Premium
Ratings
Charlie Haywood Reiterates Buy on Genmab, Keeps DKK 2,500 Price Target on Strength of Late-Stage Pipeline and Favorable Risk-Reward
22d ago
GMAB
Genmab (OTC) Maps Catalyst-Rich Path After Strong Q1
PremiumCompany Announcements
Genmab (OTC) Maps Catalyst-Rich Path After Strong Q1
23d ago
GMAB
Analyst Maintains Buy on Genmab as Expanded Petosemtamab Phase III Program Strengthens Late-Stage HNSCC Outlook
PremiumRatings
Analyst Maintains Buy on Genmab as Expanded Petosemtamab Phase III Program Strengthens Late-Stage HNSCC Outlook
23d ago
GMAB
PremiumRatings
Genmab: Buy Rating Reiterated on Strong Clinical Catalysts, Unchanged DKK 2,500 Price Target
28d ago
GMAB
Genmab Earnings Call: Strong Growth, Big Pipeline Bets
PremiumCompany Announcements
Genmab Earnings Call: Strong Growth, Big Pipeline Bets
28d ago
GMAB
Genmab Updates Articles of Association, Expands Capital and Incentive Authorizations
PremiumCompany AnnouncementsGenmab Updates Articles of Association, Expands Capital and Incentive Authorizations
29d ago
6K
GMAB
Genmab Announces Minor Capital Increase Following Employee Warrant Exercise
Premium
Company Announcements
Genmab Announces Minor Capital Increase Following Employee Warrant Exercise
1M ago
6K
GMAB
Genmab price target lowered to DKK 2,250 from DKK 2,400 at Deutsche Bank
Premium
The Fly
Genmab price target lowered to DKK 2,250 from DKK 2,400 at Deutsche Bank
1M ago
GMAB
Genmab announces 5.08% stake by Orbis Investment
PremiumThe Fly
Genmab announces 5.08% stake by Orbis Investment
1M ago
GMAB
Genmab Discloses Orbis as 5.08% Major Shareholder
PremiumCompany Announcements
Genmab Discloses Orbis as 5.08% Major Shareholder
1M ago
6K
GMAB
Yaron Werber Reiterates Hold on Genmab, Citing Strong Execution but 2026‑Weighted Catalyst Risk Profile
PremiumRatings
Yaron Werber Reiterates Hold on Genmab, Citing Strong Execution but 2026‑Weighted Catalyst Risk Profile
1M ago
GMAB
Genmab Terminates Early-Stage GEN1057 Cancer Trial: What Investors Should Watch Next
PremiumCompany Announcements
Genmab Terminates Early-Stage GEN1057 Cancer Trial: What Investors Should Watch Next
1M ago
GMAB
Genmab Halts Early-Stage GEN1286 Cancer Trial: What Investors Should Know
PremiumCompany AnnouncementsGenmab Halts Early-Stage GEN1286 Cancer Trial: What Investors Should Know
1M ago
GMAB
Genmab price target lowered to $33 from $34 at Morgan Stanley
Premium
The Fly
Genmab price target lowered to $33 from $34 at Morgan Stanley
1M ago
GMAB
Genmab: Buy Rating Reiterated as 2026 Pivotal Data Catalysts and Strong Epkinly Momentum Make 15% Share Pullback an Attractive Entry Point
Premium
Ratings
Genmab: Buy Rating Reiterated as 2026 Pivotal Data Catalysts and Strong Epkinly Momentum Make 15% Share Pullback an Attractive Entry Point
1M ago
GMAB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >